Alnylam ALN-APP-001: Phase I, Placebo-Controlled Trial of ALN-APP in Participants with Early-Onset Alzheimer’S Disease

Jared Brosch, MD

Principal Investigator

Status: Recruiting Ages: 18 Years - 100 Years Gender: All Genders Phase: 1 3 Locations

Brief Description

Who is Eligible

Ages 18+
Must have had symptoms of Alzheimer’s disease prior to age 65
Diagnosis of Alzheimer’s disease
Must be able to complete MRI
Must be able to tolerate lumbar puncture
No history of seizures, stroke or cancer in the last 5 years

What is Involved

In-person visits at IUH Neuroscience Center and University Hospital
Participants will receive at least one dose of medication injected by a physician into their spinal canal with local anesthesia. Participants will stay overnight at University Hospital directly following the first injection of medication.
Participation will last 6 months to 12 months following administration, for blood work and imaging analysis

Compensation

Compensation available via payment card for each completed appointment

Detailed Description

Eligibility of study

Interested in participating?

Enrollment in IU School of Medicine clinical trials is managed through our All IN for Health program. Many studies only accept people who are part of an invited group. Visit allinforhealth.info to connect with the study team, or contact your doctor to see if you are eligible.

Connect with the study team